Denmark-based Genmab A/S has set the price of its previously announced initial public offering on the US Nasdaq market giving gross proceeds of $505.9 million. If underwriters of the IPO exercise an option to purchase more shares, the total could rise to $581.8 million.

Boehringer Ingelheim GmbH has acquired a private Swiss biotechnology company with a therapeutic cancer vaccine targeting late-stage colorectal cancer. AMAL Therapeutics SA has developed a vaccine that is based on a fusion protein designed to activate killer T cells to target and destroy a tumour while boosting immunological memory to prevent a relapse.